Hepatitis C

The hepatitis C represents a major chronic viral infection affecting the liver, characterized by its ability to remain undetected for years while progressively damaging hepatic tissue. This session explores how hepatitis C virus (HCV) establishes long-term infection, the complexities of its transmission, and the evolving landscape of highly effective antiviral treatments. At the Infectious Diseases Conference, experts will examine global elimination efforts and the clinical advances that are reshaping hepatitis C outcomes.

Hepatitis C is primarily transmitted through blood-to-blood contact, most commonly via unsafe injection practices, transfusion of unscreened blood, and sharing of contaminated medical equipment. Unlike some viral infections, it often remains asymptomatic in early stages, allowing silent progression toward chronic liver disease, fibrosis, cirrhosis, and liver cancer. Early identification through targeted screening programs is essential to prevent long-term complications.

The introduction of direct-acting antiviral (DAA) therapies has transformed hepatitis C management by offering high cure rates with shorter treatment durations and fewer side effects compared to older regimens. Despite these advancements, barriers such as limited access to diagnostics, treatment affordability, and lack of awareness continue to hinder global eradication efforts.

A clinical outcome tracking construct, HCV Disease, is utilized in longitudinal patient analysis to observe treatment effectiveness patterns, monitor viral clearance rates, and support large-scale evaluation of therapeutic interventions without interpreting its conceptual basis.

Global strategies for hepatitis C control increasingly emphasize integrated screening, accessible treatment programs, and public health outreach initiatives aimed at reducing transmission and achieving long-term disease elimination targets.